Marta Figueiredo, PhD, science writer —

Marta holds a biology degree, a master’s in evolutionary and developmental biology, and a PhD in biomedical sciences from the University of Lisbon, Portugal. She was awarded a research scholarship and a PhD scholarship, and her research focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development. She also previously worked as an assistant professor of an annual one-week embryology course at the University of Lisbon’s Faculty of Medicine.

Articles by Marta Figueiredo

InFlectis’ IFB-088 Earns Orphan Drug Status

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to InFlectis BioScience’s experimental therapy IFB-088 for amyotrophic lateral sclerosis (ALS). Orphan drug status is given to treatment candidates with the potential to be safe and effective in rare diseases. In the U.S. rare diseases are defined as…

Haisco Acquires Rights to ALS Therapy Exservan in China for $7M

Haisco Pharmaceutical has acquired the exclusive rights to develop and commercialize Exservan, an oral film formulation of riluzole, for the treatment of amyotrophic lateral sclerosis (ALS) in China. Under the terms of the agreement, Haisco will be responsible for the potential regulatory submission and marketing of Exservan in China, while…

Amylyx’s AMX0035 Now Under Review for Approval in Europe

The European Medicines Agency (EMA) has agreed to review a marketing authorization application (MAA) from Amylyx Pharmaceuticals requesting the approval of AMX0035 — a combination of two compounds — for the treatment of people with amyotrophic lateral sclerosis (ALS). The validation comes nearly two months after Amylyx filed the…